Advertisement

Melanoma pp 323-335 | Cite as

Mohs Surgery for Melanoma In Situ

  • Joy Kunishige
  • John Zitelli
Chapter

Abstract

This chapter discusses the history and current treatment of melanoma in situ (MIS), with emphasis on the current evidence available. Removing the entire lesion is paramount, particularly as up to 67% of MIS contain invasive components. Evidence that a 1 cm margin is needed to clear 97% of melanoma in situ is presented, with even wider margins needed in some cases on the head and neck. When a 1 cm margin is anatomically impractical, Mohs surgery should be employed to attempt narrower surgical margins and achieve higher cure rates. Cure rates for wide local excision of MIS are 8–20% versus 1–2% with Mohs surgery. The use of Mohs surgery and other techniques to enable histologic evaluation of the entire peripheral margin is outlined. Advantages of Mohs surgery include tissue conservation, repair only after guaranteed clear margins, repair on the same day, and cure rates of ~99%. High cure rates are the norm, even on the head and neck and in recurrent cases. This chapter concludes with clinical scenarios that illustrate the multiple benefits of Mohs surgery for MIS.

Keywords

Melanoma in situ Lentigo maligna Surgical margin Melanoma treatment Mohs surgery Staged excision Guidelines 

Notes

Acknowledgement

Funding: None

The authors have no conflicts of interest to declare.

References

  1. 1.
    Hutchinson J. Notes on the cancerous process and on new growths in general. Arch Surg (London). 1890;2:83–6.Google Scholar
  2. 2.
    Dubreuilh MW. Lentigo malin des viellards. Ann Dermatol Syphil (Paris). 1894;5:1092–9.Google Scholar
  3. 3.
    Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 1997;36:913.CrossRefPubMedGoogle Scholar
  4. 4.
    Connolly KL, Busam KJ, Nehal KS. Optimizing outcomes for cutaneous head and neck melanoma. JAMA Dermatol. 2017;153(3):267–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Lawrence CM, Rahim R, Charlton F, Husain A. Prospective study of ​formalin-fixed mohs surgery and haematoxylin and eosin stains ​with control contralateral biopsies for lentigo maligna: 5-year ​follow-up results. Br J Derm. 2014;171:298–303.CrossRefGoogle Scholar
  6. 6.
    Dawn ME, Dawn AG, Miller SJ. Mohs surgery for the treatment of MIS: a review. Dermatol Surg. 2007;33:395–402.PubMedGoogle Scholar
  7. 7.
    Mahoney MH, Joseph M, Temple CL. The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery. J Surg Oncol. 2005;91(2):120–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Huilgol SC, Selva D, Chen C, Hill DC, James CL, et al. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol. 2004;140:1087–92.CrossRefPubMedGoogle Scholar
  9. 9.
    Bub J, Berg D, Slee A, Odland P. Management of lentigo maligna and lentigo maligna melanoma with staged excision. Arch Dermatol. 2004;140:552–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Megahed M, Schon M, Selimovic D, Schon MP. Reliability of diagnosis of melanoma in situ. Lancet. 2002;359:1921–2.CrossRefPubMedGoogle Scholar
  11. 11.
    Osborne JE, Hutchinson PEA. follow-up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision. Br J Plast Surg. 2002;55:611–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Zalla MJ, Lim KK, Dicaudo DJ, Gagnot MM. Mohs micrographic excision of melanoma using immunostains. Dermatol Surg. 2000;26:771–84.CrossRefPubMedGoogle Scholar
  13. 13.
    Somach SC, Taira JW, Pitha JV, Everett MA. Pigmented lesions in actinically damaged skin: histopathologic comparison of biopsy and excision specimens. Arch Dermatol. 1996;132:1297–302.CrossRefPubMedGoogle Scholar
  14. 14.
    Weedon D. A reappraisal of melanoma in situ. J Dermatol Surg Oncol. 1982;8:774–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Wayte DM, Helwig EB. Melanotic freckle of Hutchinson. Cancer. 1968;21:893–911.CrossRefPubMedGoogle Scholar
  16. 16.
    Gardner KH, Hill DE, Wright AC, Brewer JD, Arpey CJ. Upstaging from melanoma in situ to invasive melanoma on the head and neck after complete surgical resection. Dermatol Surg. 2015;41:1122–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Kessides MC, Wheless L, Hoffman-Bolton J, Clipp S, Alani RM, et al. Cigarette smoking and malignant melanoma: a case-control study. J Am Acad Dermatol. 2011;64(1):84–90.CrossRefPubMedGoogle Scholar
  18. 18.
    Crissione VD, Weinstock MA. Melanoma thickness trends in the United States, 1988–2006. J Invest Dermatol. 2010;130(3):793–7.CrossRefGoogle Scholar
  19. 19.
    Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129:1666–74.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Chen ST, Geller AC, Tsao H. Update on the epidemiology of melanoma. Curr Dermatol Rep. 2013;2:24–34.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Farshad A, Burg G, Pannizzon R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol. 2002;146(6):1042.CrossRefPubMedGoogle Scholar
  22. 22.
    Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg. 2008;34:147–51.CrossRefPubMedGoogle Scholar
  23. 23.
    Fisher GH, Lang PG. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol. 2003;139:945–7.CrossRefPubMedGoogle Scholar
  24. 24.
    DeBloom JRII, Zitelli JA, Brodland DG. Invasive growth potential of residual melanoma and MIS. Dermatol Surg. 2010;36:1251–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Diagnosis and treatment of early melanoma. NIH Consensus Statement. 1991;20:1–26.Google Scholar
  26. 26.
    Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. Dermatol Surg. 2011;66(3):438–44.Google Scholar
  27. 27.
    Felton S, Taylor RS, Srivastava D. Excision margins for melanoma in situ on the head and neck. Dermatol Surg. 2016;42:327–34.CrossRefPubMedGoogle Scholar
  28. 28.
    Etzkorn JR, Sobanko JF, Elenitsas R, Newman JG, Goldbach H, et al. Low recurrence rates for in situ and invasivemelanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging and margin assessment. Dermatol Surg. 2015;72(5):840–50.Google Scholar
  29. 29.
    Bienert TN, Trotter MJ, Arlette JP. Treatment of cutaneous melanoma of the face by Mohs micrographic surgery. J Cutan Med Surg. 2003;7:25–30.CrossRefPubMedGoogle Scholar
  30. 30.
    Clayton BD, Leshin B, Hitchcock MG, Marks M, White WL. Utility of rush paraffin-embedded tangential sections in the management of cutaneous neoplasms. Dermatol Surg. 2000;26:671–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Albertini JG, Elston DM, Libow LF, Smith SB, Farley MF. Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique. Dermatol Surg. 2002;28:656–65.PubMedGoogle Scholar
  32. 32.
    Moyer JS, Rudy S, Boonstra PS, Kraft C, Chinn SB, et al. Efficacy of staged excision with permanent section margin control for cutaneous head and neck melanoma. JAMA Dermatol. 2017;153(3):282–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Agarwal-Antal N, Bowen GM, Gerwels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol. 2002;47:743–8.CrossRefPubMedGoogle Scholar
  34. 34.
    deVries K, Greveling K, Prens LM, Munte K, Koljenovic S, et al. Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision. Br J Dermatol. 2016;174(3):588–93.CrossRefGoogle Scholar
  35. 35.
    Hilari H, Llorca D, Traves V, Villanueva A, Serra-Guillen C, et al. Conventional surgery compared with slow Mohs microscopic surgery in the treatment of lentigo maligna: a retrospective study of 62 cases. Actas Dermosifiliogr. 2012;103:614–23.CrossRefPubMedGoogle Scholar
  36. 36.
    Bricca GM, Brodland DG, Ren D, Zitelli JA. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52:92–100.CrossRefPubMedGoogle Scholar
  37. 37.
    Bene NI, Healy C, Coldiron BM. Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases. Dermatol Surg. 2008;34:660–4.PubMedGoogle Scholar
  38. 38.
    Abide JM, Nahai F, Bennett RG. The meaning of surgical margins. Plast Reconstr Surg. 1984;73:492–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Kimyai-Asadi A, Katz T, Goldberg LH, Ayala GB, Wang SQ, et al. Margin involvement after the excision of melanoma in situ: the need for complete en face examination of the surgical margins. Dermatol Surg. 2007;33:1434–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Johnson TM, Headington JT, Baker SR, Lowe L. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the “square” procedure. J Am Acad Dermatol. 1997;37(5 pt 1):758–64.CrossRefPubMedGoogle Scholar
  41. 41.
    Pitman GH, Kopf AW, Bart RS, Casson PR. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol. 1979;5:727–37.CrossRefPubMedGoogle Scholar
  42. 42.
    Coleman WP III, Davis RS, Reed RJ, Krementz ET. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol. 1980;6:476–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Jejurikar SS, Borschel G, Johnson TM, Lowe L, Brown DL. Immediate, optimal reconstruction of facial lentigo maligna and melanoma following total peripheral margin control. Plast Reconstr Surg. 2007;120(5):1249–55.CrossRefPubMedGoogle Scholar
  44. 44.
    Moller MG, Pappas-Politis E, Zager JS, Santiago LA, Yu D, et al. Surgical management of melanoma in situ using a staged marginal and central excision technique. Ann Surg Oncol. 2009;16(6):1526–36.CrossRefPubMedGoogle Scholar
  45. 45.
    Anderson KW, Baker SR, Lowe L, Su L, Johnson TM. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch Facial Plast Surg. 2001;3(3):202–6.CrossRefPubMedGoogle Scholar
  46. 46.
    Bosbous MW, Dzwierzynski WW, Neuburg M. Staged excision of lentigo maligna and lentigo maligna melanoma: a 10-year experience. Plast Reconstr Surg. 2009;124(6):1947–55.CrossRefPubMedGoogle Scholar
  47. 47.
    Nasrati A, Berliner JG, Goel S, McGuire J, Morhenn V, et al. Outcomes of melanoma ins itu treated with Mohs micrographic surgery compared with wide local excision. JAMA Dermatol. 2017;153(5):436–41.  https://doi.org/10.1001/jamadermatol.2016.6138.CrossRefGoogle Scholar
  48. 48.
    Hou JL, Reed KB, Knudson RM, Mirzoyev SA, Lohse CM, et al. Five-year outcomes of wide excision and Mohs micrographic surgery for primary lentigo maligna in an academic practice cohort. Dermatol Surg. 2015;41(2):211–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Hill DC, Gramp AA. Surgical treatment of lentigo maligna and lentigo maligna melanoma. Australas J Dermatol. 1999;40(1):25–30.CrossRefPubMedGoogle Scholar
  50. 50.
    Malhotra R, Chen C, Huilgol SC, Hill DC, Selva D. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Opthalmology. 2003;110(10):2011–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Walling HW, Scupham RK, Bean AK, Ceilley RI. Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 2007;57(4):659–64.CrossRefPubMedGoogle Scholar
  52. 52.
    Lee MR, Ryman WJ. Treatment of lentigo maligna with total circumferential margin control using vertical and horizontal permanent sections: a retrospective study. Australas J Dermatol. 2008;49(4):196–201.CrossRefPubMedGoogle Scholar
  53. 53.
    Valentin-Nogueras SM, Brodland DG, Zitelli JA, Gonzalez-Sepulveda L, Nazario CM. Mohs micrographic surgery using MART-1 immunostain in the treatment of invasive melanoma and melanoma in situ. Dermatol Surg. 2016;42(6):733–44.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Bricca GM, Brodland DG, Zitelli JA. Immunostaining melanoma frozen sections: the one hour protocol. Dermatol Surg. 2004;30:403–8.PubMedGoogle Scholar
  55. 55.
    Hendi A, Brodland DG, Zitelli JA. Melanocytes in long-stnading sun-exposed skin: quantitative analysis using the MART-1 immunostain. Arch Dermatol. 2006;142(7):871–6.CrossRefPubMedGoogle Scholar
  56. 56.
    Zitelli JA, Moy RL, Abell E. The reliability of frozen sections in the evaluation of surgical margins for melanoma. J Am Acad Dermatol. 1991;24:102–6.CrossRefPubMedGoogle Scholar
  57. 57.
    Sroa N, Campbell S, Ravitskiy L. Immunohistochemistry in Mohs micrographic surgery: a review of the literature. J Clin Aesthet Dermatol. 2009;2(7):37–42.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Veronesi U, et al. Narrow excision (1-cm margin). Arch Surg. 1991;126:431–41.CrossRefGoogle Scholar
  59. 59.
    Cohn-Cedermark G, et al. Long term results of a RCT by Swedish Melanoma Study Group on 2 versus 5-cm. Cancer. 2000;89:495–501.Google Scholar
  60. 60.
    Balch CM, et al. Long-term results of 2cm vs. 4cm margins for 740 patients with 1-4mm melanoma. Ann Surg Oncol. 2001;8:101–8.PubMedGoogle Scholar
  61. 61.
    Khayat D, et al. Surgical margins in melanoma 2cm versus 5cm for lesions less than 2.1mm. Cancer. 2003;97:1941–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Gillgren P, et al. 2 versus 4cm surgical excision margins for melanoma thicker than 2mm. Lancet. 2011;378:1635–42.CrossRefPubMedGoogle Scholar
  63. 63.
    Hayes et al. Wide versus narrow excision margins for high-risk melanoma: longterm follow up. Lancet Once. 2016;17:184–92.CrossRefGoogle Scholar
  64. 64.
    Mangold AR, Skinner R, Dueck AC, Sekulic A, Pockaj BA. Risk factors predicting positive margins at primary wide local excision of cutaneous melanoma. Dermatol Surg. 2016;42:646–52.CrossRefPubMedGoogle Scholar
  65. 65.
    Gerami P, Cook RW, Wilkinson J, Russell MC, Dhillon N, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21(1):175–83.CrossRefPubMedGoogle Scholar
  66. 66.
    Gerami P, Scolyer RA, Xu X, Elder DE, Abraham RM, et al. Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am J Surg Pathol. 2013;37(5):676–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Gannon CJ, Rousseau DL, Ross MI, Johnson MM, Lee JE, et al. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006;107(11):2647–52.CrossRefPubMedGoogle Scholar
  68. 68.
    Ravitskiy L, Brodland DG, Zitelli JA. Cost analysis: Mohs micrographic surgery. Dermatol Surg. 2012;38(4):585–94.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Joy Kunishige
    • 1
  • John Zitelli
    • 2
  1. 1.Department of Plastic SurgeryZitelli & Brodland Skin Cancer Center, University of Pittsburgh Medical CenterPittsburghUSA
  2. 2.Departments of ENT and Plastic SurgeryZitelli & Brodland Skin Cancer Center, University of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations